Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

Neurology. 2019 Mar 12;92(11):543. doi: 10.1212/WNL.0000000000007085.

Authors

Amit Bar-Or¹, Richard A Grove², Jerry M Tolson³, Frederick J Derosier³, Monica C Lopez⁴, Sarah T Kavanagh⁵, Aaron E Miller⁶

Affiliations

¹ (Philadelphia).
² (Uxbridge, UK).
³ (Raleigh, NC).
⁴ (Research Triangle Park, NC).
⁵ (Apex, NC).
⁶ (New York).

PMID: 30858245
DOI: 10.1212/WNL.0000000000007085

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Humans
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
ofatumumab